KR101400306B1 - A Method for Preparing of Salt and Salt Prepared by the Method - Google Patents
A Method for Preparing of Salt and Salt Prepared by the Method Download PDFInfo
- Publication number
- KR101400306B1 KR101400306B1 KR1020110143514A KR20110143514A KR101400306B1 KR 101400306 B1 KR101400306 B1 KR 101400306B1 KR 1020110143514 A KR1020110143514 A KR 1020110143514A KR 20110143514 A KR20110143514 A KR 20110143514A KR 101400306 B1 KR101400306 B1 KR 101400306B1
- Authority
- KR
- South Korea
- Prior art keywords
- salt
- present
- licorice
- angelica gigas
- result
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 98
- 238000000034 method Methods 0.000 title abstract description 26
- 241000202807 Glycyrrhiza Species 0.000 claims abstract description 35
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 35
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 35
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 35
- 229940010454 licorice Drugs 0.000 claims abstract description 35
- 240000001810 Angelica gigas Species 0.000 claims abstract description 28
- 235000018865 Angelica gigas Nutrition 0.000 claims abstract description 28
- 238000010438 heat treatment Methods 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 208000026935 allergic disease Diseases 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 42
- 229960001340 histamine Drugs 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 18
- 239000008280 blood Substances 0.000 abstract description 18
- 230000036772 blood pressure Effects 0.000 abstract description 17
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 17
- 206010020772 Hypertension Diseases 0.000 abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 11
- 230000009467 reduction Effects 0.000 abstract description 11
- 239000008103 glucose Substances 0.000 abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 8
- 241000699670 Mus sp. Species 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 7
- 230000001631 hypertensive effect Effects 0.000 abstract description 6
- 230000004580 weight loss Effects 0.000 abstract description 6
- 230000003247 decreasing effect Effects 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 5
- 208000008589 Obesity Diseases 0.000 abstract description 4
- 235000013373 food additive Nutrition 0.000 abstract description 4
- 239000002778 food additive Substances 0.000 abstract description 4
- 235000020824 obesity Nutrition 0.000 abstract description 4
- 239000013585 weight reducing agent Substances 0.000 abstract description 2
- 235000002639 sodium chloride Nutrition 0.000 description 99
- 230000000052 comparative effect Effects 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 239000011780 sodium chloride Substances 0.000 description 12
- 235000012343 cottonseed oil Nutrition 0.000 description 10
- 239000002385 cottonseed oil Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000037406 food intake Effects 0.000 description 9
- 239000003925 fat Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 5
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 5
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000125175 Angelica Species 0.000 description 3
- 102000015427 Angiotensins Human genes 0.000 description 3
- 108010064733 Angiotensins Proteins 0.000 description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 241000382455 Angelica sinensis Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241001105098 Angelica keiskei Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003011 anion exchange membrane Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/40—Table salts; Dietetic salt substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
Abstract
본 발명은 (a) 천연소금을 개방용기에 첨가하고 가열하여 상기 천연소금의 수분을 90% 증발시키는 단계; (b) 상기 단계 (a)의 결과물에 감초 및 당귀를 첨가하고 2-10분 동안 가열하는 단계; 및 (c) 상기 단계 (b)의 결과물에서 감초 및 당귀를 제거하는 단계를 포함하는 소금의 제조방법 및 상기 방법에 의해 제조된 소금에 관한 것이다. 본 발명의 방법에 의해 제조된 소금은 고지방 식이 고혈압 마우스에서 우수한 체중 감소율 및 혈압 감소율을 나타내었으며, 당뇨 개선에 대한 임상 실험 결과 혈당 수치가 유의적으로 감소하였으며, 히스타민 유리 억제율이 매우 높음을 알 수 있어 히스타민에 의해서 유발되는 피부 알레르기 질환의 예방 또는 치료에 우수한 효과를 나타내었으며, 체질 개선의 효과도 기대된다. 또한, 본 발명의 소금은 체질 개선 용도, 그리고 체중 감소를 통한 비만, 고혈압, 당뇨병 및 알레르기 질환의 예방 또는 치료 용도를 가져, 약제학적 조성물, 식품 첨가제 또는 식품 조성물로 적용할 수 있다.(A) adding natural salt to an open vessel and heating to evaporate the natural salt water to 90%; (b) adding licorice and Angelica gigas to the result of step (a) and heating for 2-10 minutes; And (c) removing the licorice and Angelica gigas from the result of step (b), and a salt produced by the method. The salt produced by the method of the present invention exhibited excellent weight loss and blood pressure reduction rate in high fat diabetic hypertensive mice. As a result of clinical trials for the improvement of diabetes, the blood glucose level was significantly decreased and the histamine release rate was very high , And showed excellent effects in the prevention or treatment of skin allergic diseases induced by histamine, and the effect of improving the constitution is also expected. In addition, the salt of the present invention can be applied as a pharmaceutical composition, a food additive or a food composition, for the purpose of improving the constitution and for preventing or treating obesity, hypertension, diabetes and allergic diseases through weight reduction.
Description
본 발명은 기능성이 부가된 건강 소금의 제조방법 및 상기 방법에 의해 제조된 건강 소금에 관한 것이다.
The present invention relates to a method for producing a functionalized health salt and a health salt produced by the method.
소금은 비중 2.16의 정육면체로서, 물에 용해되면 전해되어 나트륨이온 Na+과 염소이온 Cl-로 해리되는 강한 전해질로서, 800℃에서 용융되고 1,400℃에서 기체가 되며, 100g의 물에 0℃에서는 35.7g, 100℃에서는 39.8g이 용해되고, 빙점 강하 작용이 있어서 포화소금용액은 -21.2℃까지 안정하며, 호염균을 제외한 대부분의 미생물에 대하여 고농도에서는 방부, 멸균작용을 나타내고, 삼투 및 탈수작용을 한다.Salt is a solid hexahedron with a specific gravity of 2.16 which, when dissolved in water, dissolves into sodium ions Na + and chloride ions Cl - , which melts at 800 ° C and becomes gas at 1,400 ° C. g and at 100 ° C, 39.8g is dissolved and the freezing point depressing action is stabilized, and the saturated salt solution is stable up to -21.2 ° C. Most microorganisms except for the basophil bacilli exhibit preservation and sterilization action at high concentration, do.
소금(염분)은 체내 혈액의 0.9 중량%, 체외로 배출되는 땀, 눈물, 소변 등에 있어서는 0.1~0.5 중량%를 점유하는 생명의 유지에 없어서는 아니 되는 주요 체 구성성분으로서, 각종 체세포의 삼투압을 결정하여 체액의 이동을 가능하게 하며 체 단백질의 용해를 가능하게 함과 동시에, 그 3차원 구조를 결정함과 아울러, 신경 세포에 있어서의 신호 전달을 위한 전위차를 생성한다.Salt (saline) is 0.9% by weight of blood in the body, 0.1% to 0.5% by weight in sweat, tears and urine discharged to the outside of the body. Thereby enabling the body fluids to migrate, allowing dissolution of the body protein, determining the three-dimensional structure thereof, and generating a potential difference for signal transmission in neurons.
삼투압의 차이로 혈액 속의 산소와 영양분이 세포 속으로 전달되고 세포 속에서 생성되는 노폐물이 혈액 속으로 이송되어 체외로 배출되며, 세포 대사 물질의 능동 수송에도 관여하는 것으로 보고되어 있다.Oxygen and nutrients in the blood are transferred into the cells due to the difference in osmotic pressure. Waste generated in the cells is transferred into the blood, discharged to the outside of the body, and is also reported to be involved in the active transport of the cellular metabolites.
또한, 염분(NaCl)이 해리되어 생성되는 음이온인 Cl-은 위에서 분비되는 위산의 생성과 혈액 중 적혈구 생성 기전에 관여하며, 따라서 염분 결핍 시에는 소화 장애나 현기증, 빈혈 증세가 나타나게 된다.In addition, Cl - , an anion formed by dissociation of NaCl, is involved in the production of gastric acid secreted from the stomach and the erythropoietic mechanism of blood, and thus, when the salt deficiency is present, digestive disorders, dizziness, and anemia occur.
염분은 다른 영양소와는 달리 일시적으로 과다하게 섭취되어도 체내에 저장되지 않으며 바로 배설된다. 물을 다량 음용할 경우에는 체내 염도가 낮아지게 되지만, 매일 반복되는 습관성 과다 섭취는 혈액을 산성화시켜서 점도 상승을 유발하므로 혈전과 동맥경화의 발병 원인이 될 수 있는 것으로 보고되어 있다.Unlike other nutrients, salinity is not stored in the body even if it is temporarily overdosed, and it is excreted immediately. When water is consumed in a large amount, the salinity of the body is lowered. However, it is reported that repeated daily habitual overdose causes acidosis of the blood and raises the viscosity, which may cause the thrombosis and arteriosclerosis.
현재까지의 많은 연구 결과는 염분의 과다 섭취가 고혈압의 유발과 깊은 관련이 있는 것으로 보고하고 있다. 특히, 안지오텐신 전환효소(angiotensin converting enzyme:ACE)는 염분 중의 Cl-에 의해 활성이 상승하는 것으로 알려져 있으며, 이 ACE는 안지오텐신 에 작용하여 혈압상승물질인 안지오텐신 를 생성한다. ACE는 혈압을 저하시키는 키닌을 분해하는 한편, 혈압을 상승시키는 안지오텐신 를 생성하는 2가지 방식으로 혈압을 상승시키는 것으로 밝혀져 있다.Many studies to date have reported that excessive intake of salt is highly related to the induction of hypertension. In particular, angiotensin converting enzyme (ACE) is known to be activated by Cl - in saline, and this ACE acts on angiotensin to produce angiotensin, a blood pressure - elevating substance. ACE has been shown to raise blood pressure in two ways to produce angiotensin, which breaks down blood pressure-lowering quinine and raises blood pressure.
따라서, Cl-에 의해서 ACE의 활성이 높아지면, 혈압이 상승하게 되는 것으로 알려져 있다.Therefore, it is known that when the activity of ACE increases by Cl - , blood pressure rises.
국제보건기구에 의한 식염의 국제적 권장량은 10 g/일이며, 4.5 g/일이면 충분한 것으로 홍보하고 있으나, 한국인의 1일 평균 섭취량은 15~20g 정도로서 식염의 섭취량이 국제적 권장기준량을 상당히 초과하고 있는 실정이며, 특정 지방에 거주하는 사람들은 1일 평균 약 46g의 과도한 섭취를 하고 있는 것으로 보고되어 있다. The international recommended amount of salt by the International Health Organization is 10 g / day and 4.5 g / day is sufficient. However, since the average daily intake of Korean is 15 ~ 20g, the intake of salt significantly exceeds the recommended international standard It is reported that people living in a specific region are over-consuming an average of about 46g a day.
한국인들의 이와 같은 염분 다 섭취 식습관은 한국에서의 고혈압, 신장염, 위염이나 위암, 당뇨 환자의 발생 빈도를 높이는 주요한 원인 중의 하나인 것으로 믿어지고 있다.
It is believed that this type of salt intake is one of the major causes of hypertension, nephritis, gastritis, gastric cancer, and diabetes in Korea.
이러하다 보니, 기능성 성분을 포함한 소금에 대한 기술의 개발 필요성이 있었으며, 이러한 기술로는 저염도 기능성 칼라소금(대한민국 특허등록 제0743970호) 및 다시마 액상 소금 제조방법(대한민국 특허등록 제0858030호) 등이 있다.
As a result, there was a need to develop a technique for salt containing a functional ingredient. Such techniques include a low-salt functional color salt (Korean Patent No. 0743970) and a method for producing sea tangle salt (Korea Patent No. 0858030) have.
이에, 본 발명자는 기능성이 부가된 건강 소금의 제조방법의 개발 필요성을 인식하였다.
Accordingly, the present inventors have recognized the necessity of developing a method for producing a health-added salt with functionality.
본 발명자는 기능성이 부가된 건강 소금의 제조방법을 개발하고자 노력하였다. 그 결과, 천연소금을 개방용기에서 가열하고, 이에 특정 함량의 감초 및 당귀를 첨가하여 추가적인 가열을 하여 소금을 제조한 결과, 고지방 식이 고혈압 마우스에서 우수한 체중 감소율 및 혈압 감소율을 나타내었으며, 당뇨 개선에 대한 임상 실험 결과 혈당 수치가 유의적으로 감소하였으며, 히스타민 유리 억제율이 매우 높음을 알 수 있어 히스타민에 의해서 유발되는 피부 알레르기 질환의 예방 또는 치료에 우수한 효과를 보임을 확인하였고, 체질 개선의 효과도 기대됨을 확인함으로써, 본 발명을 완성하였다.The present inventors have sought to develop a method for producing health-added salt with functionality. As a result, natural salt was heated in an open container, and then added with a specific amount of licorice and Angelica gigas and further heated to produce salt. As a result, excellent fat reduction rate and blood pressure reduction rate were shown in high fat diabetic hypertensive mouse, As a result of the clinical test, the blood glucose level was significantly decreased and the inhibition rate of histamine release was very high. Thus, it was confirmed that it showed excellent effect in prevention or treatment of skin allergic diseases caused by histamine, and the effect of improving the constitution is also expected Thereby completing the present invention.
따라서, 본 발명의 목적은 소금의 제조 방법을 제공하는데 있다.Accordingly, an object of the present invention is to provide a method for producing salt.
본 발명의 다른 목적은 상술한 본 발명의 방법에 의해 제조된 소금을 제공하는데 있다.
Another object of the present invention is to provide a salt produced by the above-described method of the present invention.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명 및 청구범위에 의해 보다 명확하게 된다.
Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention and claims.
본 발명의 일 양태에 따르면, 본 발명은 다음의 단계를 포함하는 소금의 제조방법을 제공한다: (a) 천연 소금을 개방용기에 첨가하고 가열하여 상기 천연 소금의 수분을 90% 증발시키는 단계; (b) 상기 단계 (a)의 결과물에 감초 및 당귀를 첨가하고 2-10분 동안 가열하는 단계; 및 (c) 상기 단계 (b)의 결과물에서 감초 및 당귀를 제거하는 단계.
According to one aspect of the present invention, the present invention provides a process for producing salt comprising the steps of: (a) adding natural salt to an open vessel and heating to evaporate the water of said natural salt by 90%; (b) adding licorice and Angelica gigas to the result of step (a) and heating for 2-10 minutes; And (c) removing licorice and Angelica gigas from the result of step (b).
본 발명자는 기능성이 부가된 건강 소금의 제조방법을 개발하고자 노력하였다. 그 결과, 천연소금을 개방용기에서 가열하고, 이에 특정 함량의 감초 및 당귀를 첨가하여 추가적인 가열을 하여 소금을 제조한 결과, 고지방 식이 고혈압 마우스에서 우수한 체중 감소율 및 혈압 감소율을 나타내었으며, 당뇨 개선에 대한 임상 실험 결과 혈당 수치가 유의적으로 감소하였으며, 히스타민 유리 억제율이 매우 높음을 알 수 있어 히스타민에 의해서 유발되는 피부 알레르기 질환의 예방 또는 치료에 우수한 효과를 보임을 확인하였고, 체질 개선의 효과도 기대됨을 확인하였다.
The present inventors have sought to develop a method for producing health-added salt with functionality. As a result, natural salt was heated in an open container, and then added with a specific amount of licorice and Angelica gigas and further heated to produce salt. As a result, excellent fat reduction rate and blood pressure reduction rate were shown in high fat diabetic hypertensive mouse, As a result of the clinical test, the blood glucose level was significantly decreased and the inhibition rate of histamine release was very high. Thus, it was confirmed that it showed excellent effect in prevention or treatment of skin allergic diseases caused by histamine, and the effect of improving the constitution is also expected Respectively.
이하, 본 발명의 소금을 제조하는 과정을 상세히 설명하면 다음과 같다:Hereinafter, the process for producing the salt of the present invention will be described in detail as follows.
(a) 천연 소금의 가열 및 수분 증발 (a) Heating of natural salt and evaporation of water
우선, 본 발명의 방법은 천연 소금을 개방용기에 첨가하고 가열하여 상기 천연 소금의 수분을 90% 증발시킨다.First, the method of the present invention adds natural salt to an open container and heat it to evaporate the moisture of the natural salt by 90%.
본 발명의 바람직한 구현예에 따르면, 상기 천연 소금은 천일염, 정제 암염, 기계염 또는 재제염이고, 보다 바람직하게는 천일염이다.According to a preferred embodiment of the present invention, the natural salt is a sun salt, a refined salt, an actinic salt or a remedy, more preferably a salt of sun.
본 발명에 이용되는 천일염(NaCl 80~85; Ca 0.2; Mg 0.5~1.0; SO4 1.0~1.5; K 0.1~0.17)은 해수를 저류지로 유입시킨 다음, 태양열 및 바람 등의 자연력을 이용하여 바닷물을 농축시켜 만들어지는 소금으로서, 우리나라에서는 서해와 남해의 염전에서 생산되며, 천일염의 염도는 일반적으로 90% 내외이고 색상은 백색과 투명색이 있으나 한국산은 기상 조건의 영향으로 염도 80% 내외의 백색 성상을 가진다.The sea salt (NaCl 80 to 85; Ca 0.2; Mg 0.5 to 1.0; SO 4 1.0 to 1.5; K 0.1 to 0.17) used in the present invention is a sea salt that is introduced into the reservoir, It is produced in the sea of Korea in the west sea and the southern sea. The salinity of the sun salt is generally 90%, the color is white and the color is transparent. However, the Korean acid is white with the salinity of around 80% .
또한, 본 발명에 이용될 수 있는 정제 암염(NaCl 99.2~99.7; Ca 0.03~0.05; Mg 0.013~0.035; SO4 0.13~0.15; K 0.01~0.02)은 지하의 암염층을 채굴하여 제염한 소금으로서, 채굴된 암염은 분쇄, 선별, 정제 가공에 의해 생산되며, 염도는 보통 96% 이상이고 색은 투명색이 일반적이나 지질에 따라서는 회색, 갈색, 적색, 청색 등의 색을 지닐 수도 있다.In addition, the salt of the refined salt (NaCl 99.2 to 99.7; Ca 0.03 to 0.05; Mg 0.013 to 0.035; SO 4 0.13 to 0.15; K 0.01 to 0.02), which can be used in the present invention, The mined rock salt is produced by crushing, screening and refining. The salinity is usually 96% or more, and the color is generally transparent, but it may be gray, brown, red or blue depending on the lipid.
그리고, 본 발명에 이용될 수 있는 기계염(NaCl 99; Ca 0.1; Mg 0.2; SO4 0.4; K 0.1)은 정제염이라고도 불러 지며, 해수를 양이온 교환막과 음이온 교환막이 교호적으로 설치된 이온교환기 사이로 통과시키면서 전기분해하고 염분 농축 해수를 증발관에 넣어 수분을 증발시키고 건조기 중에서 건조시켜 제조되는 소금으로서, 일반적으로 염화나트륨의 순도가 99% 이상이고 쓴맛을 나타내는 마그네슘염이 제거되어 흡습성이 적고 백색을 띤다.The mechanical salt (NaCl 99; Ca 0.1; Mg 0.2; SO 4 0.4; K 0.1), which can be used in the present invention, is also referred to as a purifying salt. The seawater is passed through an ion exchanger provided with alternating cation exchange membrane and anion exchange membrane Electrolysis and Salt Concentration Salt is produced by placing seawater in an evaporator to evaporate water and drying it in a drier. In general, sodium chloride has a purity of 99% or more and a bituminous magnesium salt is removed, resulting in less hygroscopicity and white color.
한편, 본 발명에 이용될 수 있는 재제염(NaCl 88; Ca 0.1~0.15; Mg 0.2~0.5; SO4 0.4~0.8; K 0.1)은 원료 소금을 용해, 탈수, 건조 등의 과정을 거친 다음, 다시 재결정화시켜 제조되는 소금(시중에서는 '꽃소금'이라 통칭됨)을 지칭하며, 일반적으로는 국내산 천일염 20%와 수입염(정제 암염) 80%를 혼합하여 약 115℃에서 약 18시간 동안 가열하여 생산되며, 염도는 90% 이상으로 비교적 높다.
The salt of NaCl 88 (Ca 0.1 to 0.15; Mg 0.2 to 0.5; SO 4 0.4 to 0.8; K 0.1), which can be used in the present invention, is dissolved, dehydrated and dried, (Commonly referred to as "Kangseolgum") manufactured by recrystallization. In general, 20% of domestic sun-salt and 80% of imported salt (refined salt) are mixed and heated at about 115 ° C. for about 18 hours to produce , Salinity is more than 90%.
본 발명의 다른 바람직한 구현예에 따르면, 상기 가열은 100-150℃로 5-30분 동안 실시하고, 보다 바람직하게는 110-140℃로 10-20분 동안 실시하고, 보다 더 바람직하게는 115-125℃로 10-20분 동안 실시한다.According to another preferred embodiment of the present invention, the heating is carried out at 100-150 ° C for 5-30 minutes, more preferably at 110-140 ° C for 10-20 minutes, more preferably at 115-140 ° C, 125 ° C for 10-20 minutes.
상기 개방용기는 열전도도가 균일한 용기라면 당업계에 공지된 다양한 개방용기를 이용할 수 있고, 바람직하게는 무쇠솥이다.The open container may be a variety of open containers known in the art if it is a container having a uniform thermal conductivity, and is preferably a fermenter.
본 발명의 특징 중 하나는 천연 소금의 가열을 밀폐하지 않은 개방된 상태에서 실시한다는 것이다. 이렇게 개방된 상태에서 가열을 실시함으로써 천연 소금에 존재하는 독성 성분(가스 상태)을 제거할 수 있고, 아울러 수분을 증발할 수 있다. 그리고, 상기 온도 및 시간 동안 가열을 실시하면 독성 성분의 제거 효과가 보다 우수하다.One of the features of the present invention is that the heating of natural salt is carried out in an unsealed open state. By performing heating in such an open state, it is possible to remove toxic components (gaseous state) present in natural salt and to evaporate water. If the heating is performed for the above temperature and time, the toxic component removal effect is more excellent.
천연 소금의 수분을 90%를 증발시켜 수분함량을 10% 함유하도록 조절하는 것은 본 발명의 방법에 의해서 제조되는 소금의 염도를 조절함과 아울러 후술할 실시예에서 명확히 입증된 체중 및 혈압 감소 효과, 혈당 수치 감소 효과 및 히스타민 유리 억제 효과를 달성하는데, 그리고 감초 및 당귀와 함께 시너지(synergic) 효과를 달성하는데 중요하다.
Controlling the moisture content of the natural salt to 90% by evaporating the water content to 10% can control the salinity of the salt produced by the method of the present invention, as well as the body weight and blood pressure reduction effect, It is important to achieve a blood sugar level reduction effect and histamine free inhibitory effect, and achieve a synergic effect with licorice and Angelica gigas.
(b) 상기 단계 (a)의 결과물에 감초 및 당귀의 첨가 및 가열 (b) adding and heating the licorice and Angelica gigas to the result of step (a)
그리고, 본 발명의 방법은 상기 단계 (a)의 결과물에 감초 및 당귀를 첨가하고 2-10분 동안 가열한다.The method of the present invention further comprises adding licorice and Angelica gigas to the result of step (a) and heating for 2-10 minutes.
본 발명에 이용되는 "감초(甘草, Glycyrrhiza uralensis FISCH.)"는 콩과의 다년생 초본으로, 감초는 한방에서 모든 약재와 조화를 이루면서 효능을 증가시킬 뿐만 아니라 완화, 진통약으로 각종 동통 및 급박증상을 완화하는데 내복용 또는 외용으로 사용되고, 그 자체가 독의 중화작용과 같은 약성이 있는 것으로 알려져 있다.The term "Licorice, Glycyrrhiza uralensis FISCH.) "is a perennial herb of soybean, and licorice is used as a medicinal or external use for relieving various pain and urgency symptoms by not only increasing the efficacy while harmonizing with all medicines in one medicine, It is known that there is a weakness such as the neutralization action of poison itself.
본 발명에 이용되는 "당귀(Angelica gigantis radix)"는 미나리(Umbelliferae)과에 속한 다년생 초목으로 토당귀(Angelica gigas Nakai, 참당귀)와 일당귀(Angelica acutiloba Kitagawa, 왜당귀) 및 중국당귀(Angelica sinensis)를 일컫는 한약재로, 냉증, 빈혈과 같은 부인과 질환에 주로 쓰이며 혈행을 수월하게 하며 조혈 및 혈류의 개선 효과가 있는 것으로 알려져 있다.As used herein, the term "Angelica gigantis radix) Is a butterflyUmbelliferae) And perennial vegetation belonging toAngelica gigas Nakai, And Angelica gigasAngelica acutiloba Kitagawa, Why Angelica) and Chinese Angelica (Angelica sinensis), Which is mainly used for gynecological diseases such as poor circulation and anemia, and it is known that blood circulation is facilitated and hematocrit and blood flow are improved.
본 발명의 바람직한 구현예에 따르면, 상기 감초 및 당귀는 중량비 1:1로 첨가한다.According to a preferred embodiment of the present invention, the licorice and Angelica gigas are added at a weight ratio of 1: 1.
본 발명의 다른 바람직한 구현예에 따르면, 상기 감초 및 당귀는 천연소금 100 중량부에 대하여 감초 10-40 중량부 및 당귀 10-40 중량부로 각각 첨가되고, 보다 바람직하게는 감초 15-35 중량부 및 당귀 15-35 중량부로 각각 첨가되며, 보다 더 바람직하게는 감초 20-30 중량부 및 당귀 20-30 중량부로 각각 첨가된다.
According to another preferred embodiment of the present invention, the licorice and Angelica gigas L. are added to 10 to 40 parts by weight of licorice and 10 to 40 parts by weight of licorice, respectively, per 100 parts by weight of natural salt, more preferably 15 to 35 parts by weight of licorice, 15 to 35 parts by weight of Angelica gigas each, and more preferably 20 to 30 parts by weight of licorice and 20 to 30 parts by weight of Angelica keiskei, respectively.
본 발명에 이용되는 감초 및 당귀는 상기 감초 및 당귀의 형태가 유지된 시판되는 약재를 구입하여 이용하였다.Licorice and Angelica gigas used in the present invention were obtained by purchasing commercially available medicinal materials in the form of licorice and Angelica gigas.
본 발명의 특징 중 다른 하나는 상기 감초 및 당귀를 분말상태나 추출물 상태로 이용하는 것이 아닌 건조된 감초 및 당귀를 상기 천연 소금과 함께 혼합하고 교반하면서 가열한다는 것이다.Another feature of the present invention is that the licorice and Angelica gigas are not used as powder or extract, but dried licorice and Angelica gigas are mixed with the natural salt and heated while stirring.
본 발명의 다른 바람직한 구현예에 따르면, 상기 가열은 100-150℃로 2-10분 동안 실시하고, 보다 바람직하게는 110-140℃로 2-7분 동안 실시하고, 보다 더 바람직하게는 115-125℃로 2-6분 동안 실시한다.
According to another preferred embodiment of the present invention, the heating is carried out at 100-150 ° C for 2-10 minutes, more preferably at 110-140 ° C for 2-7 minutes, more preferably at 115-140 ° C, 125 ° C for 2-6 minutes.
(c) 상기 단계 (b)의 결과물에서 감초 및 당귀의 제거 (c) removing the licorice and Angelica gigas from the result of step (b)
마지막으로, 본 발명의 방법은 상기 단계 (b)의 결과물에서 감초 및 당귀를 제거하는 단계를 포함한다.Finally, the method of the present invention comprises removing licorice and Angelica gigas from the result of step (b).
상기 감초 및 당귀는 가열하는 과정에서 타기 전에 제거한다.
The Licorice and Angelica gigas are removed before burning in the process of heating.
이러한 방법으로 제조하면 기능성이 부가된 건강 소금을 제조할 수 있다.When prepared by this method, a health-added salt with functionality can be produced.
본 발명의 방법에 의해 제조된 소금은 고지방 식이 고혈압 마우스에서 우수한 체중 감소율 및 혈압 감소율을 나타내었으며, 당뇨 개선에 대한 임상 실험 결과 혈당 수치가 유의적으로 감소하였으며, 히스타민 유리 억제율이 매우 높음을 알 수 있어 히스타민에 의해서 유발되는 피부 알레르기 질환의 예방 또는 치료에 우수한 효과를 보임을 확인하였고, 체질 개선의 효과도 기대됨을 확인하였다.
The salt produced by the method of the present invention exhibited excellent weight loss and blood pressure reduction rate in high fat diabetic hypertensive mice. As a result of clinical trials for the improvement of diabetes, the blood glucose level was significantly decreased and the histamine release rate was very high And it is confirmed that it exerts an excellent effect in the prevention or treatment of skin allergic diseases caused by histamine, and it is confirmed that the effect of improving the constitution is also expected.
본 발명의 다른 양태에 따르면, 상술한 본 발명의 방법에 의해 제조된 소금을 제공한다. According to another aspect of the present invention, there is provided a salt produced by the above-described method of the present invention.
본 발명의 소금은 상술한 본 발명의 소금의 제조방법에 의해 제조되는 것으로서, 이 둘 사이에 공통된 내용은 반복 기재에 따른 명세서의 과도한 복잡성을 피하기 위하여, 그 기재를 생략한다.
The salt of the present invention is produced by the above-described method for producing salt of the present invention, and the description common to both of them is omitted in order to avoid excessive complexity of the specification according to the repeated description.
본 발명의 소금은 체질 개선 용도, 그리고 체중 감소를 통한 비만, 고혈압, 당뇨병 및 알레르기 질환의 예방 또는 치료 용도를 갖는다.The salt of the present invention has a use for improving the constitution and for the prevention or treatment of obesity, hypertension, diabetes and allergic diseases through weight loss.
본 발명은 상술한 본 발명의 방법에 의해 제조된 소금을 유효성분으로 포함하는 약제학적 조성물 또는 식품 첨가제로 제조될 수 있다.
The present invention can be produced by a pharmaceutical composition or a food additive containing the salt prepared by the above-described method of the present invention as an active ingredient.
약제학적 조성물로 제조되는 경우에, 본 발명의 조성물은 (a) 상술한 본 발명의 방법에 의해 제조된 소금의 약제학적 유효량 및 (b) 약제학적으로 허용되는 담체를 포함한다.When prepared with a pharmaceutical composition, the composition of the present invention comprises (a) a pharmaceutically effective amount of the salt prepared by the above-described method of the present invention, and (b) a pharmaceutically acceptable carrier.
본 발명의 약제학적 조성물에 포함되는 약제학적으로 허용되는 담체는 제제시에 통상적으로 이용되는 것으로서, 탄수화물류 화합물(예: 락토스, 아밀로스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 셀룰로스 등), 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 염 용액, 알코올, 아라비아 고무, 식물성 기름(예: 옥수수 기름, 목화 종자유, 두유, 올리브유, 코코넛유), 폴리에틸렌 글리콜, 메틸 셀룰로스, 메틸히드록시 벤조에이트, 프로필히드록시 벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약제학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences(19th ed., 1995)에 상세히 기재되어 있다.The pharmaceutically acceptable carrier to be contained in the pharmaceutical composition of the present invention is a carbohydrate-based compound (for example, lactose, amylose, dextrose, sucrose, sorbitol, mannitol, starch, cellulose, etc.) Corn oil, cottonseed oil, cottonseed oil, cottonseed oil, cottonseed oil, cottonseed oil, cottonseed oil, cottonseed oil, cottonseed oil, cottonseed oil, cottonseed oil, But are not limited to, polyethylene glycol, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations include, but are not limited to, Remington's Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약제학적 조성물은 경구 또는 비경구로 투여할 수 있고, 바람직하게는 경구 투여이다.The pharmaceutical composition of the present invention can be administered orally or parenterally, preferably orally.
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량을 용이하게 결정 및 처방할 수 있다. 본 발명의 바람직한 구현예에 따르면, 적합한 투여량은 성인 기준으로 1일 1회 50-10g이다.The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate and responsiveness of the patient, Usually, a skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment of the invention, a suitable dose is 50-10 g once daily on an adult basis.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기내에 내입시켜 제조될 수 있다. 이때, 제형은 오일 또는 수성 매질 중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.
The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. Here, the formulations may be in the form of solutions, suspensions or emulsions in an oil or aqueous medium, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
본 발명의 방법의 의해 제조된 소금을 식품 첨가제로 이용하는 경우에는 식품에 첨가함으로써 이용할 수 있고, 상기 소금을 유효성분으로 식품 조성물을 제조할 수 있다.When the salt prepared by the method of the present invention is used as a food additive, it can be used by adding it to food, and a food composition can be prepared from the salt as an active ingredient.
식품 조성물로 제조되는 경우에는 본 발명의 조성물은 상술한 본 발명의 소금 이외에 식품 제조 시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함할 수 있다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등 디사카라이드, 예를 들어, 말토스, 슈크로스, 올리고당 등 및 폴리사카라이드, 예를 들어, 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서는 천연 향미제[타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등)] 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다.In the case of a food composition, the composition of the present invention may contain components that are conventionally added in the manufacture of foods other than the salt of the present invention as described above. For example, proteins, carbohydrates, fats, nutrients, . ≪ / RTI > Examples of the above-mentioned carbohydrates include, but are not limited to, monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose, oligosaccharides and the like and polysaccharides such as dextrin, cyclodextrin and the like And sugar alcohols such as xylitol, sorbitol, and erythritol. Examples of the flavoring agent include natural flavoring agents [tau martin, stevia extract (for example, rebaudioside A and glycyrrhizin)] and synthetic flavors (for example, saccharin and aspartame).
예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 상술한 본 발명의 소금 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다.
For example, when the food composition of the present invention is prepared as a drink, it may further contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, .
본 발명의 특징 및 이점을 요약하면 다음과 같다:The features and advantages of the present invention are summarized as follows:
(ⅰ) 본 발명은 (a) 천연소금을 개방용기에 첨가하고 가열하여 상기 천연소금의 수분을 90% 증발시키는 단계; (b) 상기 단계 (a)의 결과물에 감초 및 당귀를 첨가하고 2-10분 동안 가열하는 단계; 및 (c) 상기 단계 (b)의 결과물에서 감초 및 당귀를 제거하는 단계를 포함하는 소금의 제조방법 및 상기 방법에 의해 제조된 소금에 관한 것이다.(I) adding (a) natural salt to an open vessel and heating to evaporate the water of said natural salt by 90%; (b) adding licorice and Angelica gigas to the result of step (a) and heating for 2-10 minutes; And (c) removing the licorice and Angelica gigas from the result of step (b), and a salt produced by the method.
(ⅱ) 본 발명의 방법에 의해 제조된 소금은 고지방 식이 고혈압 마우스에서 우수한 체중 감소율 및 혈압 감소율을 나타내었으며, 당뇨 개선에 대한 임상 실험 결과 혈당 수치가 유의적으로 감소하였으며, 히스타민 유리 억제율이 매우 높음을 알 수 있어 히스타민에 의해서 유발되는 피부 알레르기 질환의 예방 또는 치료에 우수한 효과를 나타내었으며, 체질 개선의 효과도 기대된다.(Ii) The salt produced by the method of the present invention exhibited excellent weight loss and blood pressure reduction rate in high fat diabetic hypertensive mice. As a result of clinical trials for the improvement of diabetes, the blood glucose level was significantly decreased and the inhibition rate of histamine And thus it has shown excellent effects in the prevention or treatment of skin allergic diseases caused by histamine, and the effect of improving the constitution is also expected.
(ⅲ) 또한, 본 발명의 소금은 체질 개선 용도, 그리고 체중 감소를 통한 비만, 고혈압, 당뇨병 및 알레르기 질환의 예방 또는 치료 용도를 가져, 약제학적 조성물, 식품 첨가제 또는 식품 조성물로 적용할 수 있다.
(Iii) The salt of the present invention can also be used as a pharmaceutical composition, a food additive or a food composition, for the purpose of improving the constitution and for preventing or treating obesity, hypertension, diabetes and allergic diseases through weight reduction.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
실시예Example
제조예 1: 소금의 제조Preparation Example 1: Preparation of salt
강원도 산으로 2-3년된 천일염 1000g을 무쇠솥에 넣고 120℃로 15분 동안 가열하면서 교반하였다. 이때, 뚜껑을 닫지 않고 교반하면서 가열을 실시하여 상기 천일염에 존재하는 독성 성분을 증발시켰다. 가열을 실시하여 천일염의 수분이 90% 정도 증발하면 감초 250g 및 당귀 250g을 첨가하고 5분 동안 120℃로 가열하면서 교반하였고, 감초 및 당귀가 타기 전에 제거하여 소금을 제조하였다. 그리고, 이를 실시예 1로 이용하였다.
Gangwon-do, 1000g of 2-3-year-old ganghwol salt was added to a steel pot and stirred at 120 ℃ for 15 minutes. At this time, heating was performed with stirring without closing the lid to evaporate toxic components present in the salt. When the water was evaporated to about 90% by heating, 250 g of licorice and 250 g of Angelica gigas were added. The mixture was stirred for 5 minutes while being heated to 120 캜, and then removed before the licorice and Angelica gigas were burned to prepare salt. This was used as Example 1.
비교제조예 1: 소금의 제조Comparative Preparation Example 1: Preparation of salt
강원도 산으로 2-3년된 천일염 1000g을 무쇠솥에 넣고 120℃로 15분 동안 가열하면서 교반하였다. 이때, 뚜껑을 닫지 않고 교반하면서 가열을 실시하여 상기 천일염에 존재하는 독성 성분을 증발시켰다. 이렇게 제조된 소금을 비교예 1로 이용하였다.
Gangwon-do, 1000g of 2-3-year-old ganghwol salt was added to a steel pot and stirred at 120 ℃ for 15 minutes. At this time, heating was performed with stirring without closing the lid to evaporate toxic components present in the salt. The thus prepared salt was used as Comparative Example 1.
비교제조예 2 및 3: 소금의 제조Comparative Production Examples 2 and 3: Preparation of salt
상기 제조예 1과 동일한 방법으로 소금을 제조하되, 감초 250g만을 첨가하여 제조하는 소금을 비교예 2로 이용하였고, 상기 제조예 1과 동일한 방법으로 소금을 제조하되, 당귀 250g만을 첨가하여 제조하는 소금을 비교예 3으로 이용하였다.
The salt was prepared in the same manner as in Preparation Example 1 except that only 250 g of licorice was added. The salt was prepared in the same manner as in Preparation Example 1 except that only 250 g of Angelica gigas Was used as Comparative Example 3.
시험예 1: 혈압과 체중에 미치는 영향에 대한 평가Test Example 1: Evaluation on blood pressure and weight
고지방 식이 고혈압 SHR 마우스 10마리씩 네 그룹으로 나누고, 식이 1kg당 실시예 1 및 비교예 1 내지 3의 소금 2g을 함유시켜 6개월간 섭취시키고 체중과 혈압변화를 측정하였다. 측정 O일 째 상기 마우스의 평균 체중은 44g이였고, 수축기 평균 혈압은 190 mmHg이였다. 1달 간격으로 측정하였고, 6개월 동안의 평균 체중 변화 및 평균 혈압의 측정 값은 아래 표 1에 정리하였다:Ten high fat diabetic hypertensive SHR mice were divided into four groups, each group containing 2 g of salt of Example 1 and Comparative Examples 1 to 3 per kg of diet for 6 months, and their body weight and blood pressure changes were measured. Measurement Day O The average weight of the mice was 44 g, and the systolic mean blood pressure was 190 mmHg. The mean body weight change and the mean blood pressure for 6 months were measured at intervals of 1 month,
상기 표 1에서 확인할 수 있듯이, 비교예 1 내지 3에 비해서, 실시예 1의 소금은 비만 및 고혈압이 유도된 마우스에 대해서 체중 감소율 및 혈압 감소율이 우수함을 확인할 수 있었다.
As shown in Table 1, it was confirmed that the salt of Example 1 was superior to the Comparative Examples 1 to 3 in weight loss rate and blood pressure reduction rate in obesity and hypertension-induced mice.
시험예Test Example 2: 당뇨개선 효과 평가 2: Evaluation of diabetic improvement
당뇨 질환을 가지고 있는 환자 2명씩 다섯 그룹으로 나누고, 무처리군, 실시예 1 및 비교예 1 내지 3의 소금을 섭취시킨 군으로 분류하였다. 그리고, 각 그룹의 환자에게 실시예 1 및 비교예 1 내지 3의 소금 5g을 6개월간 섭취하도록 하고, 소금 섭취 전 및 후의 혈당 변화를 측정하여 소금에 의한 당뇨 개선 효과를 관찰하였다. 상기 당뇨 환자의 평균 공복혈당은 153.2 mg/dL이었다. 평균 혈당 측정 값은 아래 표 2에 정리하였다:Patients with diabetes mellitus were divided into five groups, each of which was divided into the untreated group, and the group ingested with the salt of Example 1 and Comparative Examples 1 to 3. Then, the patients in each group were given 5 g of salt of Example 1 and Comparative Examples 1 to 3 for 6 months, and blood sugar changes before and after the ingestion of the salt were measured to observe the effect of improving the diabetes by the salt. The mean fasting blood glucose of the diabetic patients was 153.2 mg / dL. Mean blood glucose measurements are summarized in Table 2 below:
상기 표 2에서 볼 수 있듯이, 비교예 1 내지 3에 비해서 실시예 1의 소금은 4주간 복용한 그룹에서 혈당 수치가 유의적으로 감소함을 확인할 수 있었다.
As can be seen from the above Table 2, it was confirmed that the blood glucose level of the salt of Example 1 was significantly lowered in the group taken for 4 weeks than those of Comparative Examples 1 to 3.
시험예Test Example 3: 3: 알러지allergy 개선 효과 평가 Evaluation of improvement effect
Type I 알레르기에 대한 효과를 확인하기 위해서, 히스타민 유리 억제효과를 실험하였다. 우선, 상기 실시예 1 및 비교예 1 내지 3의 소금 각각을 Balb/C 마우스에 실험을 시작하기 2주 전부터 실험이 끝날 때까지 음용시켰다. 상기 실시예 1 및 비교예 1 내지 3 소금의 투여량은 100 mg/kg이다.In order to confirm the effect on Type I allergies, histamine inhibition effect was examined. First, each of the salts of Example 1 and Comparative Examples 1 to 3 was inoculated into Balb / C mice 2 weeks before the start of the experiment until the end of the experiment. The dose of salt of Example 1 and Comparative Examples 1 to 3 was 100 mg / kg.
이어, OVA(obalbumin, Sigma)로 3차 면역 후 2일 뒤에 마우스의 전혈(whole blood) 0.5 ml를 채취하고, 여기에 0.5 N HClO4 2 ml를 첨가하여 진탕 후 원심분리(12,000 rpm, 20 min 및 4℃)하였다. 상층액 2 ml를 분리하여 증류수 3 ml 및 n-부탄올 10 ml를 첨가하고, 고체 NaCl를 침전이 생겨 더 이상 녹지 않을 때까지 볼텍싱을 해주면서 조금씩 첨가한 후 6 N NaOH을 0.2 ml 첨가하여 원심분리하였다. 원심 분리 결과 얻어진 부탄올 층 3 ml에 n-헵탄 3 ml와 0.1 N HCl 1.2 ml를 넣고 100℃ 워터배스에서 10분 동안 방치한 후 원심분리(3,000 rpm, 15 min 및 4℃)하였다. 또한, 원심 분리 결과 얻어진 HCl층 1 ml에 1 N NaOH 0.15 ml와 0.2% OPT(o-phthaldialdehyde, Sigma) 0.1 ml를 넣고 0℃에서 40분 동안 반응시킨 후 0.5 N H2SO4 0.14 ml를 첨가하고 히스타민(0-200 mg)/0.1 N HCl 1 ml를 분주한 후 1 N NaOH 0.15 ml와 0.2% OPT 0.1 ml를 첨가한 후 0℃에서 40분 동안 반응시켰다. 이에, 0.5 N H2SO4 0.14 ml를 첨가하고 형광강도측정기(FP-6200, JASCO, 일본)를 이용하여 여기(excitation) 파장 350 nm와 방출(emission) 파장 440 nm에서 석영 큐벳을 사용하여 형광광도를 측정하였다. 히스타민 분비의 억제율은 다음의 수학식 1을 이용하여 계산하였다:Two days after the third immunization with OVA (obalbumin, Sigma), 0.5 ml of whole blood of a mouse was collected. 2 ml of 0.5 N HClO 4 was added thereto, followed by shaking, centrifugation (12,000 rpm, 20 min And 4 < 0 > C). Separate 2 ml of the supernatant, add 3 ml of distilled water and 10 ml of n-butanol, boil until the solid NaCl is precipitated and vortex until no more, add 0.2 ml of 6 N NaOH, centrifuge Respectively. 3 ml of n-heptane and 1.2 ml of 0.1 N HCl were added to 3 ml of the obtained butanol layer, and the mixture was allowed to stand in a water bath at 100 ° C for 10 minutes and centrifuged at 3,000 rpm for 15 min and 4 ° C. In addition, 0.15 ml of 1 N NaOH and 0.1 ml of 0.2% OPT (o-phthalaldehyde, Sigma) were added to 1 ml of the HCl layer obtained as a result of the centrifugation and reacted at 0 ° C for 40 minutes. Then, 0.14 ml of 0.5 NH 2 SO 4 was added Histamine (0-200 mg) / 0.1 N HCl (1 ml) was added and 0.15 ml of 1 N NaOH and 0.1 ml of 0.2% OPT were added and reacted at 0 ° C for 40 minutes. Then 0.14 ml of 0.5 NH 2 SO 4 was added and fluorescence intensity was measured using a quartz cuvette at an excitation wavelength of 350 nm and an emission wavelength of 440 nm using a fluorescence intensity meter (FP-6200, JASCO, Japan) Were measured. The percent inhibition of histamine release was calculated using the following equation:
수학식Equation 1 One
억제율(%) = (소금을 부가하기 않았을 때의 히스타민 양 - 소금을 부가했을 때의 히스타민 양) / 소금을 부가하지 않았을 때의 히스타민 양 X 100Inhibition rate (%) = (amount of histamine when salt is not added-amount of histamine when salt is added) / amount of histamine when salt is not added X 100
상기 표 3에서 볼 수 있듯이, 비교예 1 내지 3에 비해서 실시예 1의 소금을 처리한 다음 OVA를 처리한 경우의 히스타민 유리 억제율이 매우 높음을 알 수 있었다. 따라서, 히스타민에 의해서 유발되는 피부 알레르기 질환의 예방 또는 치료에 우수한 효과를 보임을 확인하였다.
As can be seen from the above Table 3, it was found that the inhibition rate of histamine glass was very high when the salt of Example 1 was treated and then treated with OVA as compared with Comparative Examples 1 to 3. Therefore, it has been confirmed that it exerts an excellent effect in the prevention or treatment of skin allergic diseases caused by histamine.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (4)
(a) 천연소금을 개방용기에 첨가하고 115-125℃로 10-20분 동안 가열하여 상기 천연소금의 수분을 90% 증발시키는 단계;
(b) 상기 단계 (a)의 결과물에 감초 및 당귀를 첨가하고 2-10분 동안 가열하되, 상기 감초 및 당귀는 천연소금 100 중량부에 대하여 감초 10-40 중량부 및 당귀 10-40 중량부로 각각 첨가되는 단계; 및
(c) 상기 단계 (b)의 결과물에서 감초 및 당귀를 제거하는 단계.
A health functional food for improving allergic diseases containing salt as an active ingredient, which comprises the following steps:
(a) adding natural salt to an open vessel and heating it to 115-125 DEG C for 10-20 minutes to 90% evaporate the moisture of the natural salt;
(b) adding licorice and Angelica gigas to the resultant of step (a), heating the mixture for 2 to 10 minutes, wherein the licorice and Angelica gigas are prepared by mixing 10-40 parts by weight of licorice and 10-40 parts by weight of licorice with 100 parts by weight of natural salt, Respectively; And
(c) removing licorice and Angelica gigas from the result of step (b).
The health functional food for improving allergic diseases according to claim 1, wherein the licorice and Angelica gigas are added at a weight ratio of 1: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110143514A KR101400306B1 (en) | 2011-12-27 | 2011-12-27 | A Method for Preparing of Salt and Salt Prepared by the Method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110143514A KR101400306B1 (en) | 2011-12-27 | 2011-12-27 | A Method for Preparing of Salt and Salt Prepared by the Method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130075218A KR20130075218A (en) | 2013-07-05 |
| KR101400306B1 true KR101400306B1 (en) | 2014-05-27 |
Family
ID=48989146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020110143514A KR101400306B1 (en) | 2011-12-27 | 2011-12-27 | A Method for Preparing of Salt and Salt Prepared by the Method |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101400306B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170024207A (en) | 2015-08-24 | 2017-03-07 | (주)영수식품 | A method for manufacturing lite salt using dietary fiber and lite salt using dietary fiber manufactured by the same |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102439859B1 (en) * | 2019-12-27 | 2022-09-02 | 조현주 | Method for manufactuinr of salt containing vagetability manural products, and the salt manufactured by the method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040028476A (en) * | 2002-09-30 | 2004-04-03 | 손옥태 | Functional green salt and manufacturing methods thereof |
| KR100772575B1 (en) * | 2006-02-02 | 2007-11-02 | 주식회사 에스티씨나라 | External composition for improvement of skin containing herbal extracts |
| KR20090053055A (en) * | 2007-11-22 | 2009-05-27 | (주) 김형민한약연구소 | Composition for preventing and/or treating dermatitis or increasing immunnity comprising natural plants extract |
| KR20090059885A (en) * | 2007-12-07 | 2009-06-11 | 주식회사 신안메이드 | Method for manufacturing functional garlic salt |
-
2011
- 2011-12-27 KR KR1020110143514A patent/KR101400306B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040028476A (en) * | 2002-09-30 | 2004-04-03 | 손옥태 | Functional green salt and manufacturing methods thereof |
| KR100772575B1 (en) * | 2006-02-02 | 2007-11-02 | 주식회사 에스티씨나라 | External composition for improvement of skin containing herbal extracts |
| KR20090053055A (en) * | 2007-11-22 | 2009-05-27 | (주) 김형민한약연구소 | Composition for preventing and/or treating dermatitis or increasing immunnity comprising natural plants extract |
| KR20090059885A (en) * | 2007-12-07 | 2009-06-11 | 주식회사 신안메이드 | Method for manufacturing functional garlic salt |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170024207A (en) | 2015-08-24 | 2017-03-07 | (주)영수식품 | A method for manufacturing lite salt using dietary fiber and lite salt using dietary fiber manufactured by the same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130075218A (en) | 2013-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105753935B (en) | Small-molecule peptides of sunflower head as well as preparation method and medical application of small-molecule peptide | |
| KR100450645B1 (en) | Enzymatic lysate of laver and uses thereof | |
| CN103637331A (en) | Okra juice drink and preparation method therefor | |
| KR101396458B1 (en) | A food or drink composition comprising fermented eastern prickly pear | |
| KR101400306B1 (en) | A Method for Preparing of Salt and Salt Prepared by the Method | |
| KR101045368B1 (en) | Composition comprising betanin as active ingredient for preventing or treating gastrointestinal disorders | |
| CN103005447B (en) | Health-care food composition with function of improving immunity and preparation method of composition | |
| JP4516958B2 (en) | Anti-diabetic composition | |
| CN101099828B (en) | Soft capsule for reducing blood pressure and improving sleeping | |
| KR20120093632A (en) | Phamaceutical composition for prevention or treatment of nephritis | |
| KR101237215B1 (en) | Phamaceutical composition for prevention or treatment of enteritis | |
| CN102138967A (en) | Application of dracocephalum moldavica L. general flavone in preparing medicament for preventing and treating cerebrovascular disease | |
| CN106962910A (en) | A kind of health composition of hypotensive | |
| CN104721800B (en) | A kind of aspirin composition and preparation method for treating coronary heart disease | |
| KR20200061285A (en) | Food Composition for blood circulation and for Preventing blood vessel disease Comprising Extract of Galangal | |
| CN106138795B (en) | Traditional Chinese medicine composition for treating premature beat and preparation method thereof | |
| KR101439792B1 (en) | Oriental medicine composition for children's underweight and respiratory organ, and oriental medicine extracts derived therefrom, and method of preparing the same | |
| CN103751255A (en) | Pachymaran composition for decreasing blood sugar and preparation method thereof | |
| CN110339229B (en) | Viscosity-reducing and blood-clearing composition and application thereof | |
| CN1650916A (en) | Chinese medical preparation for treating fullness and pain in stomach duct and abdomen | |
| KR102242797B1 (en) | A composition for improving, preventing and treating of necroptosis related diseases comprising burdock extract | |
| KR20040072193A (en) | Korean mistletoe extract having anti-hypertensive activity and the extraction method of its active substances | |
| KR100609105B1 (en) | Functional food for treatment of diabetes and preparing method thereof | |
| KR20000074868A (en) | Composition for sexual dysfunction(3) | |
| CN104352784B (en) | It is a kind of to treat stomach and the Chinese patent drug of dudenal disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E90F | Notification of reason for final refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20170522 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20180521 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20190521 Year of fee payment: 6 |